Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free IDHC Stock Alerts

Integrated Diagnostics (IDHC) Competitors

Integrated Diagnostics logo
GBX 0.52 +0.01 (+2.35%)
As of 05:55 AM Eastern
Compare

IDHC vs. VRCI, AGL, GENI, PRM, and DMTR

Should you buy Integrated Diagnostics stock or one of its competitors? MarketBeat compares Integrated Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Integrated Diagnostics include Verici Dx (VRCI), ANGLE (AGL), GENinCode (GENI), Proteome Sciences (PRM), and Deepmatter Group (DMTR). These companies are all part of the "diagnostics & research" industry.

How does Integrated Diagnostics compare to Verici Dx?

Integrated Diagnostics (LON:IDHC) and Verici Dx (LON:VRCI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Integrated Diagnostics has higher revenue and earnings than Verici Dx. Verici Dx is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00
Verici Dx£3.66M2.53-£6.56M-£0.90N/A

Integrated Diagnostics has a beta of 0.376, meaning that its share price is 62% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.256, meaning that its share price is 26% more volatile than the broader market.

7.7% of Integrated Diagnostics shares are held by institutional investors. Comparatively, 7.9% of Verici Dx shares are held by institutional investors. 71.3% of Integrated Diagnostics shares are held by company insiders. Comparatively, 1.3% of Verici Dx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Integrated Diagnostics has a net margin of 17.20% compared to Verici Dx's net margin of -193.05%. Integrated Diagnostics' return on equity of 38.79% beat Verici Dx's return on equity.

Company Net Margins Return on Equity Return on Assets
Integrated Diagnostics17.20% 38.79% 9.69%
Verici Dx -193.05%-138.93%-26.14%

In the previous week, Verici Dx had 1 more articles in the media than Integrated Diagnostics. MarketBeat recorded 1 mentions for Verici Dx and 0 mentions for Integrated Diagnostics. Integrated Diagnostics' average media sentiment score of 0.00 beat Verici Dx's score of -1.31 indicating that Integrated Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
Integrated Diagnostics Neutral
Verici Dx Negative

Summary

Integrated Diagnostics beats Verici Dx on 9 of the 13 factors compared between the two stocks.

How does Integrated Diagnostics compare to ANGLE?

ANGLE (LON:AGL) and Integrated Diagnostics (LON:IDHC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

ANGLE has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.376, suggesting that its stock price is 62% less volatile than the broader market.

Integrated Diagnostics has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ANGLE£2.62M2.89-£21.76M-£4.80N/A
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00

Integrated Diagnostics has a net margin of 17.20% compared to ANGLE's net margin of -1,444.04%. Integrated Diagnostics' return on equity of 38.79% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
ANGLE-1,444.04% -191.36% -29.89%
Integrated Diagnostics 17.20%38.79%9.69%

In the previous week, ANGLE's average media sentiment score of 1.28 beat Integrated Diagnostics' score of 0.00 indicating that ANGLE is being referred to more favorably in the media.

Company Overall Sentiment
ANGLE Positive
Integrated Diagnostics Neutral

17.5% of ANGLE shares are held by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are held by institutional investors. 2.7% of ANGLE shares are held by company insiders. Comparatively, 71.3% of Integrated Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Integrated Diagnostics beats ANGLE on 9 of the 12 factors compared between the two stocks.

How does Integrated Diagnostics compare to GENinCode?

GENinCode (LON:GENI) and Integrated Diagnostics (LON:IDHC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

In the previous week, GENinCode's average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score.

Company Overall Sentiment
GENinCode Neutral
Integrated Diagnostics Neutral

GENinCode has a beta of 0.593, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.376, meaning that its stock price is 62% less volatile than the broader market.

Integrated Diagnostics has higher revenue and earnings than GENinCode. GENinCode is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GENinCode£3.08M1.88-£6.10M-£2.08N/A
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00

11.4% of GENinCode shares are held by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are held by institutional investors. 8.4% of GENinCode shares are held by company insiders. Comparatively, 71.3% of Integrated Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Integrated Diagnostics has a net margin of 17.20% compared to GENinCode's net margin of -185.47%. Integrated Diagnostics' return on equity of 38.79% beat GENinCode's return on equity.

Company Net Margins Return on Equity Return on Assets
GENinCode-185.47% -409.40% -63.99%
Integrated Diagnostics 17.20%38.79%9.69%

Summary

Integrated Diagnostics beats GENinCode on 8 of the 11 factors compared between the two stocks.

How does Integrated Diagnostics compare to Proteome Sciences?

Proteome Sciences (LON:PRM) and Integrated Diagnostics (LON:IDHC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Integrated Diagnostics has a net margin of 17.20% compared to Proteome Sciences' net margin of -81.50%. Integrated Diagnostics' return on equity of 38.79% beat Proteome Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Proteome Sciences-81.50% 33.80% -19.25%
Integrated Diagnostics 17.20%38.79%9.69%

In the previous week, Proteome Sciences' average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score.

Company Overall Sentiment
Proteome Sciences Neutral
Integrated Diagnostics Neutral

Proteome Sciences has a beta of 0.148, suggesting that its stock price is 85% less volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.376, suggesting that its stock price is 62% less volatile than the broader market.

Integrated Diagnostics has higher revenue and earnings than Proteome Sciences. Proteome Sciences is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteome Sciences£3.76M1.77-£4.08M-£1.04N/A
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00

0.0% of Proteome Sciences shares are owned by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are owned by institutional investors. 36.7% of Proteome Sciences shares are owned by insiders. Comparatively, 71.3% of Integrated Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Integrated Diagnostics beats Proteome Sciences on 10 of the 11 factors compared between the two stocks.

How does Integrated Diagnostics compare to Deepmatter Group?

Integrated Diagnostics (LON:IDHC) and Deepmatter Group (LON:DMTR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Integrated Diagnostics has higher revenue and earnings than Deepmatter Group. Deepmatter Group is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integrated Diagnostics£8.35B0.00£4.01T£250.030.00
Deepmatter Group£1.04M0.00N/A-£0.30N/A

Integrated Diagnostics has a net margin of 17.20% compared to Deepmatter Group's net margin of 0.00%. Integrated Diagnostics' return on equity of 38.79% beat Deepmatter Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Integrated Diagnostics17.20% 38.79% 9.69%
Deepmatter Group N/A N/A N/A

In the previous week, Integrated Diagnostics' average media sentiment score of 0.00 equaled Deepmatter Group'saverage media sentiment score.

Company Overall Sentiment
Integrated Diagnostics Neutral
Deepmatter Group Neutral

7.7% of Integrated Diagnostics shares are held by institutional investors. 71.3% of Integrated Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Integrated Diagnostics beats Deepmatter Group on 8 of the 8 factors compared between the two stocks.

Get Integrated Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IDHC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IDHC vs. The Competition

Export
MetricIntegrated DiagnosticsDiagnostics & Research IndustryMedical SectorLON Exchange
Market Cap£3.04M£693.09M£6.96B£2.77B
Dividend Yield1.67%3.36%2.68%6.12%
P/E Ratio0.0073.0427.20368.14
Price / Sales0.00581.72578.1384,676.43
Price / CashN/A11.4249.2527.89
Price / Book0.003.1310.747.50
Net Income£4.01T£334.07B£3.59B£5.89B
7 Day Performance2.35%-1.19%-1.92%-0.04%
1 Month Performance-9.69%0.75%2.23%-1.39%
1 Year Performance58.18%6.74%23.82%61.97%

Integrated Diagnostics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IDHC
Integrated Diagnostics
N/AGBX 0.52
+2.4%		N/A+46.6%£3.04M£8.35B0.006,692
VRCI
Verici Dx
N/AGBX 0.37
+5.7%		N/A-75.2%£11.05M£3.66MN/A19
AGL
ANGLE
N/AGBX 2.35
-11.3%		N/A-53.0%£7.58M£2.62MN/A650
GENI
GENinCode
N/AGBX 0.80
-6.5%		N/A-60.7%£5.99M£3.08MN/A2,300
PRM
Proteome Sciences
N/AGBX 1.30
-33.3%		N/A-29.2%£4.56M£3.76MN/A240

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:IDHC) was last updated on 7/17/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel